APPLICATION
ANDA214654
TYPE
ANDA
ORIGINAL APPROVAL
2021-08-06
LATEST ACTION
2025-09-17
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 150MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
Approval history
2025-09-17Labeling · Supplement 22 · standardAP
2024-01-30Labeling · Supplement 3 · standardAP
2024-01-30Labeling · Supplement 1 · standardAP
2024-01-30Labeling · Supplement 14 · standardAP
2024-01-30Labeling · Supplement 8 · standardAP
2024-01-30Labeling · Supplement 6 · standardAP
2021-08-06UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.